CN1701792A - Preparation for external use on skin - Google Patents
Preparation for external use on skin Download PDFInfo
- Publication number
- CN1701792A CN1701792A CN 200510074305 CN200510074305A CN1701792A CN 1701792 A CN1701792 A CN 1701792A CN 200510074305 CN200510074305 CN 200510074305 CN 200510074305 A CN200510074305 A CN 200510074305A CN 1701792 A CN1701792 A CN 1701792A
- Authority
- CN
- China
- Prior art keywords
- ascorbic acid
- weight
- skin
- skin preparations
- extenal use
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 55
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 204
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 104
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 96
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 96
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 48
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960003237 betaine Drugs 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims description 9
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 30
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000006210 lotion Substances 0.000 abstract 1
- 230000003020 moisturizing effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 69
- 239000000203 mixture Substances 0.000 description 49
- -1 amine salt Chemical class 0.000 description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 230000002087 whitening effect Effects 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 241001597008 Nomeidae Species 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 235000002639 sodium chloride Nutrition 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000002211 L-ascorbic acid Substances 0.000 description 8
- 235000000069 L-ascorbic acid Nutrition 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 8
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000003078 antioxidant effect Effects 0.000 description 7
- 235000013599 spices Nutrition 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 244000007729 Malpighia coccigera Species 0.000 description 4
- 235000014791 Malpighia coccigera Nutrition 0.000 description 4
- 240000003394 Malpighia glabra Species 0.000 description 4
- 235000014837 Malpighia glabra Nutrition 0.000 description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 3
- XDBMXUKHMOFBPJ-ZAFYKAAXSA-N L-ascorbic acid 2-sulfate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OS(O)(=O)=O)=C1O XDBMXUKHMOFBPJ-ZAFYKAAXSA-N 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 229960003720 enoxolone Drugs 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- GDSOZVZXVXTJMI-SNAWJCMRSA-N (e)-1-methylbut-1-ene-1,2,4-tricarboxylic acid Chemical compound OC(=O)C(/C)=C(C(O)=O)\CCC(O)=O GDSOZVZXVXTJMI-SNAWJCMRSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 2
- 229920002079 Ellagic acid Polymers 0.000 description 2
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 108010020346 Polyglutamic Acid Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000013877 carbamide Nutrition 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 229960002852 ellagic acid Drugs 0.000 description 2
- 235000004132 ellagic acid Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- 229940065115 grapefruit extract Drugs 0.000 description 2
- 229960002350 guaiazulen Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- VVIUBCNYACGLLV-UHFFFAOYSA-N hypotaurine Chemical compound [NH3+]CCS([O-])=O VVIUBCNYACGLLV-UHFFFAOYSA-N 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940041616 menthol Drugs 0.000 description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229940026510 theanine Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- CDOZUFMQVAYOSF-PQYRJTSOSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;phosphoric acid Chemical compound OP(O)(O)=O.OP(O)(O)=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CDOZUFMQVAYOSF-PQYRJTSOSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XLGIIESZTMTMCL-UHFFFAOYSA-N 2,2-dihydroxyhexan-3-one Chemical compound CCCC(=O)C(C)(O)O XLGIIESZTMTMCL-UHFFFAOYSA-N 0.000 description 1
- SURVRMRLLSFWHA-UHFFFAOYSA-N 3-(dimethylazaniumyl)butanoate Chemical compound CN(C)C(C)CC(O)=O SURVRMRLLSFWHA-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 description 1
- PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 description 1
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004260 Potassium ascorbate Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical class OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- TUYRNAGGIJZRNM-LBHUVFDKSA-N [(2s)-2-[(2r)-4-hexadecanoyloxy-3-hydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethyl] hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCCCCCCCCCCCCCC)=C1O TUYRNAGGIJZRNM-LBHUVFDKSA-N 0.000 description 1
- 229960001009 acetylcarnitine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940072065 ascorbic acid 2-sulfate Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002169 ethanolamines Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- DJFBJKSMACBYBD-UHFFFAOYSA-N phosphane;hydrate Chemical group O.P DJFBJKSMACBYBD-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000019275 potassium ascorbate Nutrition 0.000 description 1
- 229940017794 potassium ascorbate Drugs 0.000 description 1
- CONVKSGEGAVTMB-RXSVEWSESA-M potassium-L-ascorbate Chemical compound [K+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] CONVKSGEGAVTMB-RXSVEWSESA-M 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000010352 sodium erythorbate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-O sulfonium Chemical compound [SH3+] RWSOTUBLDIXVET-UHFFFAOYSA-O 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
This skin lotion containing at least one kind selected from the ascorbic acid or its derivatives uses diglycerol and a low molecular weight betaine simultaneously for improving the percutaneous absorption amount of the ascorbic acid or its derivatives, exhibiting the improving effects for blotches and somberness sufficiently and also having an excellent moisturizing effect.
Description
Technical field
The present invention relates to the skin preparations for extenal use that percutaneous absorbability is good and moisture retention is high of a kind of ascorbic acid or ascorbic acid derivates.
Background technology
As everyone knows, ascorbic acid is brought into play so-called anti-inflammatory effect, acne and is improved the synthetic cell-stimulating effects of biotic component such as effect, whitening effect, antiageing effect, antioxidant effect, promotion collagen, suppresses the cell injury of keratinization of epidermis cell under action of ultraviolet radiation or the various effects of the effect of DNA damage, wishes these effects and is widely used in skin preparations for extenal use.In order to give full play to the effect of this preparation, the Transdermal absorption amount of need give a piece of bad advice hematic acid or bad hematic acid derivant increases, promotes the effectively device of absorption.
On the other hand, with the trimethyl glycine is the low molecule betaine of representative, be widely used in skin preparations for extenal use as wetting agent, for example by share carbamide and low molecule betaine, can obtain very excellent pachylosis and improve effect (the patent documentation spy opens flat 9-48720 communique), by cooperating whitening composition, low molecule betaine, silicone oil, improve the percutaneous absorbability (spy opens the 2001-89321 communique) of whitening agent etc.
Summary of the invention
Problem of the present invention is to provide a kind of skin preparations for extenal use that contains ascorbic acid or ascorbic acid derivates, the Transdermal absorption amount height of its ascorbic acid or ascorbic acid derivates, have the effect of improving of sufficient brown patch, skin dimness, also have good moistening effect simultaneously.
The inventor etc. have carried out research with keen determination in order to solve above-mentioned problem, found that in containing one or more the skin preparations for extenal use that is selected from ascorbic acid or the ascorbic acid derivates, if share diglycerol and low molecule betaine, then can improve the percutaneous absorbability of ascorbic acid or ascorbic acid derivates, bring into play the effect of improving for brown patch, skin dimness that these materials have fully, moistening effect is good simultaneously.
Be that the present invention is following invention.
1. skin preparations for extenal use contains (A) and is selected from one or more material, (B) diglycerol and (C) low molecule betaine in ascorbic acid or the ascorbic acid derivates.
2. according to above-mentioned 1 described skin preparations for extenal use, wherein low molecule betaine is a trimethyl glycine.
3. according to above-mentioned 1 or 2 described skin preparations for extenal use, be to be used for anti-wrinkle, the anti-skin preparations for extenal use that relaxes and/or preserve moisture.
4. according to each described skin preparations for extenal use in above-mentioned 1～3, contain the diglycerol of the ascorbic acid of (A) 0.1～30 weight % or ascorbic acid derivates, (B) 1～95 weight % and (C) trimethyl glycine of 0.5～9 weight %.
5. according to each described skin preparations for extenal use in above-mentioned 1～4, contain the diglycerol of the ascorbic acid of (A) 5～20 weight % or ascorbic acid derivates, (B) 1～10 weight % and (C) trimethyl glycine of 1～8 weight %.
In addition, in this manual if do not have particular determination, % to be meant weight %.
In the present invention, by share one or more material, diglycerol and the low molecule betaine that is selected from ascorbic acid or the ascorbic acid derivates (below be also referred to as the ascorbic acid class), can significantly improve the Transdermal absorption amount of ascorbic acid or ascorbic acid derivates.Therefore, can provide the action effect of ascorbic acid or ascorbic acid derivates to be given full play to, brown patch and skin dimness etc. improve the good skin preparations for extenal use of effect.In addition, in skin preparations for extenal use of the present invention, can prevent the xerosis cutis effect and protect skin, can also keep very high skin moisture-keeping power simultaneously based on ascorbic acid or ascorbic acid derivates are distinctive.Therefore, if use skin preparations for extenal use of the present invention, the power of preserving moisture of skin improves, and brown patch, the dimness of skin improve, and elasticity, the elastic force of skin significantly improve.Like this, can provide good skin preparations for extenal use according to the present invention with anti-wrinkle effect, anti-relexation, moisture-keeping function etc.
The specific embodiment
Ascorbic acid that uses among the present invention or ascorbic acid derivates, can use in the goods or cosmetic field outside medicine, medicine, as the composition of skin preparations for extenal use and commercially available ascorbic acid or ascorbic acid derivates, they typically refer to the goods of L body.
In addition, ascorbic acid or ascorbic acid derivates can use the salt that allows as pharmaceutically, for example can enumerate with the salt of organic base (for example, the salt of front three amine salt, triethylamine salt, monoethanolamine salt, triethanolamine salt, pyridiniujm etc. and tertiary amine, alkaline ammonium salt such as arginine etc.) and salt (for example, the ammonium salt of inorganic base, alkali metal salt such as sodium salt, potassium salt, alkali salt such as calcium salt, magnesium salt, aluminum salt etc.) etc., particularly preferred salt is sodium salt, potassium salt.Specifically, can be exemplified as sodium ascorbate, potassium ascorbate etc.
In the present invention, can be used in combination ascorbic acid or ascorbic acid derivates more than a kind or 2 kinds.
Above-mentioned ascorbic acid of the present invention, preferred material in the ascorbic acid derivates is an ascorbic acid, the phosphate derivative of ascorbic acid, the sulfate derivative of ascorbic acid, the cetylate derivant of ascorbic acid, the ether derivant of ascorbic acid, the ascorbic acid phosplate of more specifically saying so, the ascorbic acid bisphosphate, the ascorbic acid triguaiacyl phosphate, ascorbic acid-2-Monosulfate, ascorbic acid-2-di-sulfate, ascorbic acid-2-three sulfuric esters, the ascorbic acid monopalmitate, Vitamin C dipalmitate, the ascorbic acid tripalmitate, ascorbic acid-2-glucoside and their salt.From safe and action effect for skin or mucosa, preferred especially ascorbic acid, ascorbic acid phosplate or their salt, ascorbic palmitate, ascorbic acid-2-glucoside.
In the present invention, can use in d body, l body and the dl body of ascorbic acid class any one.In external agent of the present invention, because the percutaneous absorbability of ascorbic acid or derivatives thereof significantly improves, therefore also can preferably use water miscible ascorbic acid or the water solublity ascorbic acid derivates (for example ester derivant of ascorbic acid or ether derivant etc.) that is considered to the Transdermal absorption difficulty usually.If enumerate the object lesson of described water solublity ascorbic acid derivates, can list the phosphate derivative of the L-ascorbic acid of L-ascorbic acid phosplate, L-ascorbic acid bisphosphate or L-ascorbic acid triguaiacyl phosphate etc. as ester derivant; Sulfuric ester as ascorbic acid can be enumerated the L-Ascorbic acid 2-sulfate.In addition, as ether derivant, can enumerate L-ascorbic acid-2-glucoside etc.Wherein, preferred L-ascorbic acid, the phosphate derivative of L-ascorbic acid, L-Ascorbic acid 2-sulfate, L-ascorbic acid-2-glucoside, from safe and action effect for skin or mucosa, preferred especially L-ascorbic acid, L-ascorbic acid phosplate, L-ascorbic acid-2-glucoside.
The ascorbic acid in the skin preparations for extenal use of the present invention or the use level of ascorbic acid derivates, with respect to the skin preparations for extenal use total weight, preferred 0.1～30 weight %.In this scope, can suit to select use level according to the various effects of needed ascorbic acid or ascorbic acid derivates or the purposes of skin preparations for extenal use.In view of effect of the present invention, further preferred 3～25 weight %, the scope of preferred especially 5～20 weight %.
In addition, the diglycerol that uses among the present invention is the known compound that is used for skin preparations for extenal use etc. more.
If the use level of the diglycerol of Shi Yonging is proved effective the present invention in the present invention, then be not particularly limited, can consider the usability of skin or effect and suitable the selection used.Usually with respect to whole skin preparations for extenal use, can be 1～95 weight %, preferred 1～50 weight %, more preferably 1～20 weight %, preferred especially 1～10 weight %.
Low molecule betaine among the present invention be meant molecular weight below 200 and intramolecularly form zwitterionic chemical compound, specifically, can be exemplified as quaternary ammonium base, quaternary phosphonium hydroxide, uncle's sulfonium base etc., they show the character as surfactant hardly.Wherein preferably use the N of following formula (1) expression, N, N-trialkyl aminoacid.
(in the formula, R
1, R
2And R
3Represent the alkyl of carbon number 1～6 independently of each other, n represents 1～6.)
As R
1～R
3, can be extensive use of the straight or branched alkyl of carbon number 1～6.Promptly, can distinguish illustration methyl, ethyl, propyl group, isopropyl, butyl, isobutyl group, sec-butyl, the tert-butyl group, amyl group, isopentyl, neopentyl, tertiary pentyl, hexyl, isohesyl, 3-methyl amyl, 2,2-dimethylbutyl or 2,3-dimethylbutyl etc.Wherein, R
1～R
3Can be identical, also can be different.
Specifically, can be exemplified as trimethyl glycine, triethyl group glycine, tripropyl glycine, the triisopropyl glycine of n=1, trimethyl-Beta-alanine of n=2, trimethyl-γ-An Jidingsuan of n=3 etc., preferred trimethyl glycine.
In addition, can replace these low molecule betaines, specifically, can be exemplified as the N of n=1, N, N-trimethylalanine, N, N, N-triethyl group alanine, N, N, N-triisopropyl alanine, N, N, N-trimethyl methylalanine, carnitine, acetylcarnitine etc., preferred carnitine.
In skin preparations for extenal use of the present invention, the use level of low molecule betaine, with respect to the skin preparations for extenal use gross weight, preferred 0.5～10 weight %, the various effects of ascorbic acid or derivatives thereof as required or the purposes of skin preparations for extenal use can suit to select in this scope.In view of effect of the present invention, further preferred 0.5～9 weight %, the scope of preferred especially 1～8 weight %.Sometimes then can not bring into play effect less than 0.1 weight %, in addition, if surpass 10 weight %, usability variation sometimes.
In skin preparations for extenal use of the present invention, match ratio in the combination of diglycerol and betaine, can suit to select, but from effect of the present invention, preferably with respect to diglycerol 1 weight portion, low molecule betaine is 0.01～10 weight portion, 0.1～7 weight portion more preferably, preferred especially 0.1～5 weight portion.
In skin preparations for extenal use of the present invention, except above-mentioned ascorbic acid or derivatives thereof, for the various effects that strengthen or additional ascorbic acid or derivatives thereof is had, in addition, can also make up whitening composition, the anti-inflammatory composition, antimicrobial component, the cell-stimulating composition, astringent component, antioxidant content, acne is improved composition, the aging resistance composition, the synthetic promotion composition of biotic components such as collagen, blood circulation promotes composition, the composition of preserving moisture, aging resistance become the various compositions that grade more than a kind or 2 kinds and cooperate, with to additional other the useful effects of skin preparations for extenal use.The composition more than a kind or 2 kinds in whitening composition, anti-inflammatory composition, antioxidant content, aging resistance composition or the composition of preserving moisture preferably.As the combination of these compositions, particularly preferably be combination, ascorbic acid or derivatives thereof and the whitening composition of combination, ascorbic acid or derivatives thereof and aging resistance composition of combination, ascorbic acid or derivatives thereof and antioxidant content of combination, ascorbic acid or derivatives thereof and whitening composition and the antioxidant content that can enumerate ascorbic acid or derivatives thereof and whitening composition and the combination of aging resistance composition.As these each compositions, the composition as goods outside medicine, the medicine or the skin preparations for extenal use in the cosmetic field can use all the time, and in addition, if the composition that uses future then is not particularly limited, any composition can suit to select to use.
For example,, can be exemplified as arbutin, ellagic acid, phytic acid, lucinol, Ka Momila ET, vitaminss such as vitamin A or derivatives thereof, vitamin E or derivatives thereof, pantothenic acid or derivatives thereof as whitening composition.Wherein, as preferred composition, can list pantothenic acid or derivatives thereof, ellagic acid, phytic acid, vitamin A or derivatives thereof, vitamin E or derivatives thereof.These whitening compositions can use more than a kind or 2 kinds.
When using above-mentioned whitening composition, be coupled to preferred 0.0003～10 weight % of ratio of skin preparations for extenal use of the present invention, more preferably 0.01～5 weight %.In addition, whitening composition is with respect to ascorbic acid or derivatives thereof 100 weight portions that contain in the skin preparations for extenal use of the present invention, wishes with 0.001～1000 weight portion, preferred 0.005～500 weight portion, more preferably the ratio of 0.01～100 weight portion cooperates.
As the anti-inflammatory composition, can list allantoin, Calamina, enoxolone or derivatives thereof, zinc oxide, Kessazulen, tocopherol acetas, pyridoxine hydrochloride, menthol, Camphora, Oleum Terebinthinae, indometacin, salicylic acid or derivatives thereof etc.Preferably allantoin, enoxolone or derivatives thereof, enoxolone or derivatives thereof, Kessazulen, menthol.
When using above-mentioned anti-inflammatory composition, be coupled to preferred 0.0003～10 weight % of ratio of skin preparations for extenal use of the present invention, more preferably 0.01～5 weight %.In addition, the anti-inflammatory composition is with respect to ascorbic acid or derivatives thereof 100 weight portions that contain in the skin preparations for extenal use of the present invention, wishes with 0.001～1000 weight portion, preferred 0.005～500 weight portion, more preferably the ratio of 0.01～100 weight portion cooperates.
As antioxidant content, can list tocopherol and derivant thereof, Butylated hydroxyanisole, dibenzylatiooluene, sodium sulfite, arabo-ascorbic acid and salt thereof, flavonoid, glutathion, glutathion peroxidase, glutathione-S-transferase, catalase, superoxide dismutase, sulfur oxidation protein, taurine, sulfenyl taurine, hypotaurine etc.Preferably tocopherol and derivant thereof, sulfenyl taurine, hypotaurine, sulfur oxidation protein, flavonoid.
When using antioxidant content, the ratio that is coupled to skin preparations for extenal use of the present invention is generally 0.00001～10 weight %, preferred 0.0001～5 weight %, more preferably 0.001～5 weight %.In addition, with respect to ascorbic acid or derivatives thereof 100 weight portions that contain in the skin preparations for extenal use of the present invention, wish with 0.001～1000 weight portion, preferred 0.005～500 weight portion, more preferably the ratio of 0.01～100 weight portion cooperates.
As the aging resistance composition, can be exemplified as biostearin (vitamin A, retinoic acid, axerophthal etc.), VITAMIN B15, kinetins, maloic acid, zingiberaceous plant Rhizoma Curcumae Longae extract, sphingol derivant, silicon, silicic acid, N-methyl-L-serine, methyl dihydroxy pentanone etc.Preferably biostearin (vitamin A, retinoic acid, axerophthal etc.), kinetins.
When using above-mentioned aging resistance composition, be coupled to preferred 0.0003～10 weight % of ratio of skin preparations for extenal use of the present invention, more preferably 0.01～5 weight %.In addition, the aging resistance composition is with respect to ascorbic acid or derivatives thereof 100 weight portions that contain in the skin preparations for extenal use of the present invention, wishes with 0.001～1000 weight portion, preferred 0.005～500 weight portion, more preferably the ratio of 0.01～100 weight portion cooperates.
As the composition of preserving moisture, except being exemplified as aminoacid and derivants thereof such as alanine, serine, leucine, isoleucine, threonine, glycine, proline, hydroxyproline, glycosamine, theanine, peptides such as collagen, collagen peptide, gelatin, glycerol, 1, polyhydric alcohol such as 3-butanediol, propylene glycol, Polyethylene Glycol, sugar alcohols such as Sorbitol, phospholipid such as lecithin, hydrolecithin, mucopolysaccharides such as hyaluronic acid, heparin, chrondroitin, outside the compositions from NMF such as lactic acid, pyrrolidone sodium carboxylate, carbamide, can also be exemplified as polyglutamic acid etc.Preferably alanine, serine, glycine, proline, hydroxyproline, glycosamine, theanine, collagen, collagen peptide, glycerol, 1,3 butylene glycol, hydrolecithin, hyaluronic acid, heparin, chrondroitin, lactic acid, pyrrolidone sodium carboxylate, polyglutamic acid.
When composition is preserved moisture in use,, can enumerate being generally 0.1～10 weight %, preferred 0.5～5 weight %, more preferably 0.5～5 weight % as the ratio that is coupled in the skin preparations for extenal use of the present invention.
Skin preparations for extenal use of the present invention can also further cooperate stabilization agent, surfactant, solvable branch, oils, saccharide or the Transdermal absorption of changing into to promote composition except cooperating above-mentioned each composition.Particularly, can further improve stability, effectiveness, the usability of the ascorbic acid or derivatives thereof in the aqueous solvent by cooperating stabilization agent, surfactant, solvable branch or the oils of changing into.
In skin preparations for extenal use of the present invention; do not damage qualities such as appearance stability or viscosity; in addition; in the scope of the amount of not damaging effect of the present invention and matter; in case of necessity in the goods or cosmetic field outside medicine, medicine; can cooperate as external agent composition and normally used various composition, as aminoacid, stimulate palliative, viscosifier, antiseptic, ultraviolet protective agent, coloring agent, dispersant, pH regulator agent, spice etc.Wherein, these compositions can cooperate independent a kind arbitrarily, also can cooperate arbitrarily more than 2 kinds.
Skin preparations for extenal use of the present invention, mix as required and cooperate above-mentioned various compositions, and then the substrate by cooperating other solvents or normally used external agent etc. in case of necessity, can be modulated into the form of pasty state, cystose, gel, liquid, emulsion state, butyrous, lamellar (the base material load is held), aerosol shape, various needs such as vaporific.They can be by this area method manufacturing commonly used.
Skin preparations for extenal use of the present invention can possess the fluidity of common pH1～8, but, wish that at preferred pH be 2～7, more preferably pH is 2～6 acidic region from the stability of ascorbic acid or derivatives thereof, to the viewpoint of the benefit of the low irritant of skin or mucosa and skin usability.
Skin preparations for extenal use of the present invention can be as cosmetics such as foundation cream, lipstick, mascara, eye shadow, eyeliner, brow and manicure materials; Foundation make up materials such as emulsion, vanishing cream, astringent, oil and facial film, detergents such as wash one's face material or cleaning agent, body detergent; Anti-Deodorant, tinea pedis therapeutic agent, pruritus, wound healing agent, wiping agent, detergent, anti-inflammatory analgesic, acne therapeutic agent, hemorrhoid, disinfection sanitizer, whitening agent, ultraviolet protective agent etc. belong to the goods outside medicine, the medicine or the various topical compositions of cosmetic field.According to the action effect to skin, the preparation that preferred the present invention is applied to skin preparations for extenal use crusts such as (crust preparations) uses.
(embodiment)
Below, further describe the present invention according to embodiment and test example, but the present invention is not limited to these embodiment etc.
(test example 1)
The skin of back of hairless mouse is clamped on the Transdermal absorption pond, be full of with normal saline by the side.Be full of with the reagent shown in the table 1 in the donor side, in two ponds, stir the limit with stirring rubber limit and under 37 ℃, be incubated.After 24 hours, measure being subjected to the ascorbic acid concentrations in the liquid of side by high-speed liquid chromatography.Measurement result is illustrated in the table 1.The result be with the ascorbic acid transit dose in the comparative example 1 (the pure solution of ascorbic acid) as 1, with its compare the expression.
Table 1
| Comparative example 1 | Comparative example 2 | Comparative example 3 | Embodiment 1 | Embodiment 2 | |
| The L-ascorbic acid | ??10％ | ??10％ | ??10％ | ??10％ | ??10％ |
| Diglycerol | ??- | ??5％ | ??- | ??5％ | ??10％ |
| Trimethyl glycine | ??- | ??- | ??5％ | ??5％ | ??2％ |
| Water | ??90％ | ??85％ | ??85％ | ??80％ | ??78％ |
| The percutaneous transit dose compares | ??1.0 | ??1.2 | ??1.5 | ??2.0 | ??1.8 |
Can confirm that from result of the test the transit dose of ascorbic acid is that the Transdermal absorption amount is collaborative to be increased with diglycerol and trimethyl glycine combination the time.Contain the skin preparations for extenal use of ascorbic acid, diglycerol and trimethyl glycine for combination,, therefore can give full play to the action effect that ascorbic acid has because more ascorbic acid is reached in the skin.
(test example 2)
To 10 Testing Team actual use comparative example 1 and embodiment 2, carried out feeling evaluation for the elastic sensation of brown patch degree of improvement, skin dimness degree of improvement, muscle, the water conservation sense of muscle.Behind the makeup water conditioning skin that a day twice back that washes one's face, utilization are used at ordinary times, carry out the entire face coating.Use at first continuously after two all comparative examples 1, use two all embodiment 2 continuously and estimate.As the benchmark of estimating, estimate embodiment 2 compare with comparative example 1 better, or roughly the same, still be to differ to estimate.Answer ratio that embodiment 2 compares with comparative example 1 and be designated as ◎, 60～80% when above 80% and be designated as zero, 50～60% and be designated as △, be lower than 50% be designated as *.In addition, use comparative example 1 and comparative example 3 to carry out same test by reality.The result is illustrated in the table 2.
Table 2
| Comparative example 3 | Embodiment 2 | |
| Brown patch degree of improvement | ??△ | ??○ |
| Skin dimness degree of improvement | ??○ | ??◎ |
| The elastic sensation of skin | ??○ | ??◎ |
| The water conservation sense of skin | ??△ | ??◎ |
Can confirm from result of the test, in embodiment 2 with diglycerol and trimethyl glycine and ascorbic acid combination, the percutaneous absorbability of ascorbic acid improves, the action effect that ascorbic acid had is given full play to, skin dimness or brown patch improve, the elastic force of skin improves, and the water conservation sense of skin improves in addition, gives full play to the recovery effects of the skin with elasticity and moistening.
Below enumerate example of formulations.
(embodiment 3)
Ascorbic acid 20
Trimethyl glycine 3
Diethylene glycol monoethyl ether 52.4
Diglycerol 4
Purified Water 20
Spice 0.5
Grapefruit extract 0.1
Add up to 100%
(embodiment 4)
Ascorbic acid 15
Trimethyl glycine 3
Diethylene glycol monoethyl ether 50.9
Propylene glycol 20
Purified Water 10
Diglycerol 1
Malpighia coccigera (Acerola) extract 0.1
Add up to 100%
(embodiment 5)
Ascorbic acid 2-sulfate 10
Trimethyl glycine 1
Diethylene glycol monoethyl ether 84.7
Diglycerol 4
Spice 0.3
Add up to 100%
(embodiment 6)
Ascorbic acid phosplate 10
Trimethyl glycine 3
Diethylene glycol monoethyl ether 65.4
Propylene glycol 20
Diglycerol 1
Malpighia coccigera (Acerola) extract 0.1
Spice 0.5
Add up to 100%
(embodiment 7)
Ascorbic acid phosplate sodium 15
Trimethyl glycine 3
Diethylene glycol monoethyl ether 50.9
Propylene glycol 20
Purified Water 10
Diglycerol 1
Malpighia coccigera (Acerola) extract 0.1
Add up to 100%
(embodiment 8)
Ascorbic acid 10
Trimethyl glycine 1
Diethylene glycol monoethyl ether 84.7
Diglycerol 4
Spice 0.3
Add up to 100%
(embodiment 9)
Ascorbic acid 10
Trimethyl glycine 3
Diethylene glycol monoethyl ether 65.4
Propylene glycol 20
Diglycerol 1
Malpighia coccigera (Acerola) extract 0.1
Spice 0.5
Add up to 100%
(embodiment 10)
Ascorbic acid-2-glucoside 20
Trimethyl glycine 3
Diethylene glycol monoethyl ether 54.2
Diglycerol 4
Purified Water 20
Spice 0.5
Grapefruit extract 0.1
Add up to 100%
Claims (5)
1. skin preparations for extenal use contains (A) and is selected from one or more material, (B) diglycerol and (C) low molecule betaine in ascorbic acid or the ascorbic acid derivates.
2. skin preparations for extenal use according to claim 1, wherein low molecule betaine is a trimethyl glycine.
3. skin preparations for extenal use according to claim 1 and 2 is to be used for anti-wrinkle, the anti-skin preparations for extenal use that relaxes and/or preserve moisture.
4. according to each described skin preparations for extenal use in the claim 1～3, contain the diglycerol of the ascorbic acid of (A) 0.1～30 weight % or ascorbic acid derivates, (B) 1～95 weight % and (C) trimethyl glycine of 0.5～9 weight %.
5. according to each described skin preparations for extenal use in the claim 1～4, contain the diglycerol of the ascorbic acid of (A) 5～20 weight % or ascorbic acid derivates, (B) 1～10 weight % and (C) trimethyl glycine of 1～8 weight %.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004160139 | 2004-05-28 | ||
| JP2004160139A JP4683861B2 (en) | 2004-05-28 | 2004-05-28 | Topical skin preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1701792A true CN1701792A (en) | 2005-11-30 |
Family
ID=35452335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510074305 Pending CN1701792A (en) | 2004-05-28 | 2005-05-25 | Preparation for external use on skin |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP4683861B2 (en) |
| CN (1) | CN1701792A (en) |
| CA (1) | CA2508093A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006290749A (en) * | 2005-04-06 | 2006-10-26 | Ichimaru Pharcos Co Ltd | Melanogenesis inhibitor |
| JP2013056866A (en) * | 2011-09-09 | 2013-03-28 | Pias Arise Kk | EXPRESSION ACTIVATING AGENT OF Bmal1 GENE AND METHOD FOR ACTIVATING EXPRESSION OF Bmal1 GENE |
| JP2015127319A (en) | 2013-11-29 | 2015-07-09 | 花王株式会社 | Skin external preparation |
| JP6605283B2 (en) * | 2015-10-02 | 2019-11-13 | 御木本製薬株式会社 | Aqueous skin preparation |
| JP7497939B2 (en) * | 2020-02-18 | 2024-06-11 | ポーラ化成工業株式会社 | Anti-dull skin |
| CN117545456A (en) * | 2021-07-21 | 2024-02-09 | 株式会社资生堂 | Cosmetic for skin permeation and method for producing cosmetic for skin permeation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63145217A (en) * | 1986-12-09 | 1988-06-17 | Taisho Pharmaceut Co Ltd | Transdermal composition |
| JPH01207220A (en) * | 1988-02-10 | 1989-08-21 | Lion Corp | Composition for skin |
| JP2000063255A (en) * | 1998-08-12 | 2000-02-29 | Shiseido Co Ltd | Preparation for external use for skin |
| JP2001089321A (en) * | 1999-09-17 | 2001-04-03 | Lion Corp | External preparation for skin |
| JP2005060236A (en) * | 2003-08-11 | 2005-03-10 | Nonogawa Shoji Kk | External preparation for skin |
-
2004
- 2004-05-28 JP JP2004160139A patent/JP4683861B2/en not_active Expired - Lifetime
-
2005
- 2005-05-20 CA CA 2508093 patent/CA2508093A1/en not_active Abandoned
- 2005-05-25 CN CN 200510074305 patent/CN1701792A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2508093A1 (en) | 2005-11-28 |
| JP4683861B2 (en) | 2011-05-18 |
| JP2005336133A (en) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1313069C (en) | Composition for hair and/or scalp | |
| JP5876962B2 (en) | Composition for external use | |
| CN103479551B (en) | Cosmetic water and preparation method | |
| CN1201723C (en) | Skin and tissue care and/or therapeutic formulations and applications thereof | |
| TW201532621A (en) | Antioxidant compositions and methods of using the same | |
| CN1113143A (en) | Cosmelic and/or dematological comporihori with a hydoplilic canvei and viramnic which can be mixed immedicarely before us | |
| CN1359285A (en) | Protective and regenerative topical dermatological agents containing idebenone | |
| CN1305460C (en) | Sugar intake promoters | |
| CN1942163A (en) | hair tonic | |
| JP2005306831A (en) | Skin preparation | |
| CA3009144A1 (en) | Personal care composition comprising taurine, arginine, glycine | |
| JPH09291011A (en) | Composition suitable for eternal use | |
| CN101909591A (en) | Emulsification of skin external preparations and cosmetics | |
| CN1701792A (en) | Preparation for external use on skin | |
| JP4564471B2 (en) | Composition suitable for external use | |
| CN1589772A (en) | Cosmetics | |
| CN1660081A (en) | skin topical | |
| JP2005225865A (en) | Skin preparation | |
| JP2008100991A (en) | Aqueous preparation with stabilized carotenoids | |
| CN103479554B (en) | Whitening and nourishing night cream and preparation method | |
| JP2017014167A (en) | Composition for cosmetics | |
| JP2016027034A (en) | Composition for external use | |
| WO2012008457A1 (en) | Composition for external application | |
| JP2012036174A (en) | Composition for external application | |
| CN1182836C (en) | Cosmetics contg. nucleic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |